Marksans Pharma Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026.

Marksans Pharma reported strong full-year FY2025-26 results with consolidated revenue from operations of Rs 30,334.71 million, up 12.8% year-on-year from Rs 26,891.74 million. Profit after tax grew 9.8% to Rs 4,200.64 million, while total comprehensive income surged 38.5% to Rs 5,962.12 million, boosted by favorable forex gains of Rs 500.95 million. The company expanded its global footprint with two new subsidiaries (Europe and Canada) incorporated in January 2026. The Board recommended a final dividend of Rs 0.90 per share (90%). Statutory auditors MSKA & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated financial statements.